{"entity":{"id":"mt-601","kind":"drug","name":"MT-601","aka":[],"tldr":"MT-601 is an experimental autologous multi-antigen recognizing T cell therapy, not genetically modified from Marker Therapeutics, in phase 1 trials for relapsed lymphoma and pancreatic cancer.","summary":"MT-601 is an autologous multi-antigen recognizing (MAR) T cell therapy, not genetically modified from Marker Therapeutics. Multi-antigen specific CD4+ and CD8+ T cells that recognise six tumour antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), designed to recognise and kill tumours without genetic modification. Its furthest stage is phase 1, for relapsed lymphoma (including after or ineligible for anti-CD19 CAR-T) and pancreatic cancer. ClinicalTrials.gov registers it in 2 studies linked below. Lymphoma study NCT05798897 recruiting (phase 1); pancreatic study NCT06549751 registered, not yet recruiting (phase 1). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Marker Therapeutics: markertherapeutics.com","url":"https://markertherapeutics.com/"},{"label":"Marker Therapeutics: markertherapeutics.com","url":"https://markertherapeutics.com/"},{"label":"Marker Therapeutics: markertherapeutics.com","url":"https://markertherapeutics.com/"},{"label":"Marker Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05798897"},{"label":"ClinicalTrials.gov: trials of MT-601","url":"https://clinicaltrials.gov/search?intr=MT-601"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","pancreatic"],"sections":[],"technologies":[],"targets":["birc5","prame","ctag1b","mage-a4","ssx2","wt1"],"drugs":[],"companies":["marker-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05798897","nct06549751"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"MT-601","modality":"Autologous multi-antigen recognizing (MAR) T cell therapy, not genetically modified","mechanism":"Multi-antigen specific CD4+ and CD8+ T cells that recognise six tumour antigens (Survivin, PRAME, NY-ESO-1, MAGE-A4, SSX2, WT-1), designed to recognise and kill tumours without genetic modification.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/mt-601/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"birc5","kind":"target","name":"BIRC5","route":"/targets/birc5/"},{"id":"ctag1b","kind":"target","name":"CTAG1B","route":"/targets/ctag1b/"},{"id":"mage-a4","kind":"target","name":"MAGE-A4","route":"/targets/mage-a4/"},{"id":"prame","kind":"target","name":"PRAME","route":"/targets/prame/"},{"id":"ssx2","kind":"target","name":"SSX2","route":"/targets/ssx2/"},{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/"}],"company":[{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/"}],"trial":[{"id":"nct06549751","kind":"trial","name":"MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer","route":"/trials/nct06549751/"},{"id":"nct05798897","kind":"trial","name":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma","route":"/trials/nct05798897/"}]}}